See All Slides - tctmd.com

Slides

Presentation TCT 2014

Against the Proposal!

Presenter: Ido Weinberg

September 14, 2014

Presentation TCT 2014

Prepare Your Team: Transforming Education and Learning

Presenter: Michael Guiry, Regina Deible, Christopher M. Nelson

September 14, 2014

Presentation TCT 2014

FFR-CT: The Game Changer? Recommended Applications in 2014/2015

Presenter: Justin E. Davies, Allen Jeremias, Nick E. J. West, Bon-Kwon Koo

September 14, 2014

Presentation TCT 2014

This Is the Sweet Spot for a MitraClip!

Presenter: Vinod H. Thourani, Mathew Williams, Saibal Kar

September 14, 2014

Presentation TCT 2014

Neurocognitive Functional Assessment After TAVR: Methodologies and Clinical Importance

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Ronald M. Lazar

September 14, 2014

Presentation TCT 2014

Conduction Disturbances (New LBBB and Pacemakers) After TAVR: Frequency, Clinical Impact, and Management Considerations

Presenter: Josep Rodés-Cabau, Mathew Williams, Azeem Latib, Tamim Nazif

September 14, 2014

Presentation TCT 2014

Valve Thrombus After TAVR: Frequency, Clinical Recognition, and Management

Presenter: Josep Rodés-Cabau, Mathew Williams, Azeem Latib

September 14, 2014

Presentation

Aortic Stenosis in the Elderly: Disease Prevalence and Number of Candidates for TAVR

Presenter: 201433|Ruben L. J. Osnabrugge

May 30, 2013

Presentation EuroPCR 2013

Two-year clinical outcomes in the EVOLVE FHU trial:A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Presenter: 203171|Ian Meredith

May 31, 2013

Presentation

What is the Best Initial Management Strategy for Stable Ischemic Heart Disease?

Presenter: 218868|Judith Hochman

May 31, 2013

Advertisement

Slides

Against the Proposal!

Prepare Your Team: Transforming Education and Learning

FFR-CT: The Game Changer? Recommended Applications in 2014/2015

This Is the Sweet Spot for a MitraClip!

Neurocognitive Functional Assessment After TAVR: Methodologies and Clinical Importance

Conduction Disturbances (New LBBB and Pacemakers) After TAVR: Frequency, Clinical Impact, and Management Considerations

Valve Thrombus After TAVR: Frequency, Clinical Recognition, and Management

Aortic Stenosis in the Elderly: Disease Prevalence and Number of Candidates for TAVR

Two-year clinical outcomes in the EVOLVE FHU trial:A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

What is the Best Initial Management Strategy for Stable Ischemic Heart Disease?

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content